RESUMEN
BACKGROUND: The foot-and-mouth disease (FMD) virus is classified into seven serotypes, of which the South African types have South African Territories (SAT)1, SAT2, and SAT3 that are prevalent in Africa. Especially SAT2 have spread to Arabian Peninsula and the Palestinian Autonomous Territories. Of these viruses, the incidence of SAT2 is the highest. It is important to prepare for the spread of the virus to other continents, even though most FMD viruses are bovine-derived. In particular, due to the high breeding density of pigs in Asia, more attention is usually paid to the immunity and protection of pigs than cattle. For this reason, this study investigated the immunity and protection of pigs against the SAT viruses. METHODS: Specific vaccines were developed for SAT1, SAT2, and SAT3 serotypes. These vaccine viruses were designed to be distinguished from the wild-type strain. An immunogenicity test was conducted using these vaccines in both cattle (n = 5/group) and pigs (n = 20/group). RESULTS: High virus-neutralizing titer of antibodies (> 1:100) was induced in only 2 weeks after the immunization of cattle with the individual vaccine for SAT1, SAT2 or SAT3, and a clear immune response was induced after the second immunization in pigs. When the vaccinated pigs (n = 4-5/group) were challenged by the homologous wild-type virus strain 4 weeks after immunization, all the pigs were protected from the challenge. CONCLUSIONS: This study confirmed that these vaccines can be used against SAT1, SAT2, and SAT3 viruses in cattle and pigs. The vaccine strains developed in this study are expected to be used as vaccines that can protect against FMD in the event of a future FMD outbreak in pigs in consideration of the situation in Asia.
Asunto(s)
Virus de la Fiebre Aftosa/inmunología , Fiebre Aftosa/prevención & control , Enfermedades de los Porcinos/prevención & control , Vacunas Virales/administración & dosificación , Vacunas Virales/inmunología , Animales , Anticuerpos Neutralizantes/sangre , Anticuerpos Antivirales/sangre , Bovinos , Enfermedades de los Bovinos/prevención & control , Virus de la Fiebre Aftosa/clasificación , Serogrupo , Porcinos , Resultado del Tratamiento , Vacunas de Productos Inactivados/administración & dosificación , Vacunas de Productos Inactivados/inmunología , Vacunas Marcadoras/administración & dosificación , Vacunas Marcadoras/inmunologíaRESUMEN
There are seven antigenically distinct serotypes of foot-and-mouth disease virus (FMDV), each of which has intratypic variants. In the present study, we have developed methods to efficiently generate promising vaccines against seven serotypes or subtypes. The capsid-encoding gene (P1) of the vaccine strain O1/Manisa/Turkey/69 was replaced with the amplified or synthetic genes from the O, A, Asia1, C, SAT1, SAT2, and SAT3 serotypes. Viruses of the seven serotype were rescued successfully. Each chimeric FMDV with a replacement of P1 showed serotype-specific antigenicity and varied in terms of pathogenesis in pigs and mice. Vaccination of pigs with an experimental trivalent vaccine containing the inactivated recombinants based on the main serotypes O, A, and Asia1 effectively protected them from virus challenge. This technology could be a potential strategy for a customized vaccine with challenge tools to protect against epizootic disease caused by specific serotypes or subtypes of FMDV.IMPORTANCE Foot-and-mouth disease (FMD) virus (FMDV) causes significant economic losses. For vaccine preparation, the selection of vaccine strains was complicated by high antigenic variation. In the present study, we suggested an effective strategy to rapidly prepare and evaluate mass-produced customized vaccines against epidemic strains. The P1 gene encoding the structural proteins of the well-known vaccine virus was replaced by the synthetic or amplified genes of viruses of seven representative serotypes. These chimeric viruses generally replicated readily in cell culture and had a particle size similar to that of the original vaccine strain. Their antigenicity mirrored that of the original serotype from which their P1 gene was derived. Animal infection experiments revealed that the recombinants varied in terms of pathogenicity. This strategy will be a useful tool for rapidly generating customized FMD vaccines or challenge viruses for all serotypes, especially for FMD-free countries, which have prohibited the import of FMDVs.
Asunto(s)
Virus de la Fiebre Aftosa/inmunología , Fiebre Aftosa/prevención & control , Vacunas Virales/inmunología , Animales , Proteínas de la Cápside/genética , Proteínas de la Cápside/inmunología , Modelos Animales de Enfermedad , Fiebre Aftosa/inmunología , Fiebre Aftosa/patología , Virus de la Fiebre Aftosa/genética , Virus de la Fiebre Aftosa/patogenicidad , Ratones , Proteínas Recombinantes/genética , Proteínas Recombinantes/inmunología , Porcinos , Vacunas de Productos Inactivados/administración & dosificación , Vacunas de Productos Inactivados/inmunología , Vacunas de Productos Inactivados/aislamiento & purificación , Vacunas Sintéticas/administración & dosificación , Vacunas Sintéticas/inmunología , Vacunas Sintéticas/aislamiento & purificación , Vacunas Virales/administración & dosificación , Vacunas Virales/aislamiento & purificaciónRESUMEN
Foot-and-mouth disease virus (FMDV) is a single-stranded, positive-sense RNA virus containing at least 13 proteins. Many of these proteins show immune modulation capabilities. As a non-structural protein of the FMDV, 2B is involved in the rearrangement of the host cell membranes and the disruption of the host secretory pathway as a viroporin. Previous studies have also shown that FMDV 2B plays a role in the modulation of host type-I interferon (IFN) responses through the inhibition of expression of RIG-I and MDA5, key cytosolic sensors of the type-I IFN signaling. However, the exact molecular mechanism is poorly understood. Here, we demonstrated that FMDV 2B modulates host IFN signal pathway by the degradation of RIG-I and MDA5. FMDV 2B targeted the RIG-I for ubiquitination and proteasomal degradation by recruiting E3 ubiquitin ligase ring finger protein 125 (RNF125) and also targeted MDA5 for apoptosis-induced caspase-3- and caspase-8-dependent degradation. Ultimately, FMDV 2B significantly inhibited RNA virus-induced IFN-ß production. Importantly, we identified that the C-terminal amino acids 126-154 of FMDV 2B are essential for 2B-mediated degradation of the RIG-I and MDA5. Collectively, these results provide a clearer understanding of the specific molecular mechanisms used by FMDV 2B to inhibit the IFN responses and a rational approach to virus attenuation for future vaccine development.
Asunto(s)
Virus de la Fiebre Aftosa , Interferón Tipo I , Aminoácidos/metabolismo , Animales , Caspasa 3/metabolismo , Caspasa 8/metabolismo , Interferón Tipo I/metabolismo , Transducción de Señal , Ubiquitina-Proteína Ligasas/metabolismo , Proteínas ViroporinasRESUMEN
The type Asia1 genetic group(G)-V lineage foot-and-mouth disease (FMD) virus was identified in the East-Asian region in 2009. To date, only Shamir has been used as a standard vaccine strain worldwide for type Asia1. To prevent type Asia1 FMD in eastern Asia, two vaccine strains (ASM-R: G-V and ASM-SM: G-V/Shamir fusion) were developed and tested against type Asia1 virus strains. After immunization with the two experimental vaccines, the ASM-SM strain showed a higher level of protection against Shamir virus in mice. Additional immunogenicity tests were carried out in cattle and pigs, revealing sufficient antibody production capable of protecting the animals against the viral challenge. In cattle, the immune response started just 2 weeks after vaccination. Immunogenicity was lower in pigs, but antibody production was greatly increased to a high level after a second vaccination round. In particular, herein, 60 % and 100 % of the vaccinated pigs challenged with the Asia1 Shamir virus were determined to be clinically protected after one and two vaccination rounds with ASM-R, respectively. Pigs vaccinated twice produced sufficient antibody titers with low virus shedding for short time. Moreover, ASM-SM single-vaccinated pigs showed 100 % protection when challenged with the Asia1 Shamir virus. In summary, the vaccine strain ASM-SM designed for the defense of the Asian region efficiently granted protection to pigs against the typical Asia1 virus, Shamir.
Asunto(s)
Anticuerpos Antivirales/sangre , Enfermedades de los Bovinos/prevención & control , Virus de la Fiebre Aftosa/inmunología , Fiebre Aftosa/prevención & control , Enfermedades de los Porcinos/prevención & control , Vacunas Virales/genética , Animales , Anticuerpos Antivirales/inmunología , Bovinos , Enfermedades de los Bovinos/virología , Asia Oriental , Femenino , Fiebre Aftosa/inmunología , Virus de la Fiebre Aftosa/genética , Inmunogenicidad Vacunal , Ratones , Ratones Endogámicos C57BL , Porcinos , Enfermedades de los Porcinos/virología , Vacunas Virales/administración & dosificación , Vacunas Virales/inmunología , Esparcimiento de VirusRESUMEN
Efforts are required to develop foot-and-mouth disease (FMD) vaccines in Asia that can respond to the type O outbreaks that have continued with the devastating damage since 2010. It is necessary to develop vaccine strains that can provide protection against the ME-SA topotype, which has tended to spread into neighboring areas, and the frequent SEA topotype outbreaks. To this end, this study aimed to develop a FMD vaccine utilizing O PanAsia-2 that is able to provide broad protection against ME-SA as the vaccine strain, with a focus on the O/Jincheon/SKR/2014 virus (SEA topotype), the outbreaks of which have persisted in spite of the enforcement of FMD vaccination. The virus neutralizing antibody (VN) titer to the ME-SA topotype (especially, Ind2001 lineage) virus in pigs was the highest, followed by SEA, while the VN titers to the Cathay and EURO-SA topotypes were similar. In the O/Jincheon/SKR/2014 virus challenge test, all pigs were protected against the virus, and almost no virus shedding was detected after the virus challenge. In the immunization test performed on cattle and pigs, antibodies with sufficient protective activity were produced in cattle two weeks after the first immunization, and pigs exhibited lower immunity compared to cattle. However, immunity was improved enough in pigs to provide protection against the virus challenge after the second immunization, with a significant increase in antibody production.
Asunto(s)
Virus de la Fiebre Aftosa , Fiebre Aftosa , Enfermedades de los Porcinos , Vacunas Virales , Animales , Anticuerpos Neutralizantes/inmunología , Anticuerpos Antivirales/inmunología , Bovinos , Fiebre Aftosa/prevención & control , Virus de la Fiebre Aftosa/clasificación , Virus de la Fiebre Aftosa/inmunología , Inmunogenicidad Vacunal , Porcinos , Enfermedades de los Porcinos/prevención & control , Vacunas Virales/inmunologíaRESUMEN
BACKGROUND: The quality of a vaccine depends strongly on the effects of the adjuvants applied simultaneously with the antigen in the vaccine. The adjuvants enhance the protective effect of the vaccine against a viral challenge. Conversely, oil-type adjuvants leave oil residue inside the bodies of the injected animals that can produce a local reaction in the muscle. The long-term immunogenicity of mice after vaccination was examined. ISA206 or ISA15 oil adjuvants maintained the best immunity, protective capability, and safety among the oil adjuvants in the experimental group. OBJECTIVES: This study screened the adjuvant composites aimed at enhancing foot-and-mouth disease (FMD) immunity. The C-type lectin or toll-like receptor (TLR) agonist showed the most improved protection rate. METHODS: Experimental vaccines were fabricated by mixing various known oil adjuvants and composites that can act as immunogenic adjuvants (gel, saponin, and other components) and examined the enhancement effect on the vaccine. RESULTS: The water in oil (W/O) and water in oil in water (W/O/W) adjuvants showed better immune effects than the oil in water (O/W) adjuvants, which have a small volume of oil component. The W/O type left the largest amount of oil residue, followed by W/O/W and O/W types. In the mouse model, intramuscular inoculation showed a better protection rate than subcutaneous inoculation. Moreover, the protective effect was particularly weak in the case of inoculation in fatty tissue. The initial immune reaction and persistence of long-term immunity were also confirmed in an immune reaction on pigs. CONCLUSIONS: The new experimental vaccine with immunostimulants produces improved immune responses and safety in pigs than general oil-adjuvanted vaccines.
Asunto(s)
Adyuvantes Inmunológicos/farmacología , Virus de la Fiebre Aftosa/inmunología , Fiebre Aftosa/prevención & control , Enfermedades de los Porcinos/prevención & control , Vacunación/veterinaria , Vacunas Virales/farmacología , Animales , Anticuerpos Antivirales/inmunología , Formación de Anticuerpos , Fiebre Aftosa/inmunología , Fiebre Aftosa/virología , Ratones , Ratones Endogámicos C57BL , Porcinos , Enfermedades de los Porcinos/inmunología , Enfermedades de los Porcinos/virología , Vacunas Virales/inmunologíaRESUMEN
Newly developed vaccine strains to prevent foot-and-mouth disease caused by the emerging serotype Asia1 virus were evaluated. To protect against the group (G)-VIII strain, which occurred recently, we produced an infectious cDNA clone of Asia1 Shamir cDNA (Asia1 Shamir-R). In addition, by adding a site 1 epitope of VP1 of the G-VIII lineage virus to this virus, we produced a new virus (Sham GVIII- EPI), and another virus(Sham GVIII-VP1) was replaced with that of G-VIII lineage in the VP1 region of Shamir. Test vaccines were produced using these three types of vaccine virus, and their immunogenicity and protection capabilities were evaluated in mice. Immunized mice were challenged with the Asia1 Shamir or G-VIII virus, and the results show that all the vaccines have similar protective effects. As they showed similar antigenicity, we chose the Shamir-R vaccine. Pigs maintained relatively high neutralizing antibody levels against homologous viruses of the Shamir and G-VII or G-VIII lineage three to four weeks after immunization. However, they formed relatively low levels of antibodies to G-IV and G-V viruses. In conclusion, we produced a vaccine candidate capable of protection against the G-VIII virus in the vaccine experiment for the type Asia1 serotype vaccine. This Shamir-R vaccine virus was found to protect against the viruses of the Asia1 genotype G-VII and G-VIII lineages, which occurred recently in Asia.
Asunto(s)
Anticuerpos Neutralizantes/sangre , Antígenos Virales/inmunología , Virus de la Fiebre Aftosa/inmunología , Fiebre Aftosa/prevención & control , Enfermedades de los Porcinos/prevención & control , Vacunas Virales/inmunología , Animales , Asia , Proteínas de la Cápside/inmunología , Epítopos/inmunología , Femenino , Fiebre Aftosa/inmunología , Virus de la Fiebre Aftosa/clasificación , Inmunogenicidad Vacunal , Ratones , Ratones Endogámicos C57BL , Serogrupo , Porcinos , Enfermedades de los Porcinos/virología , VacunaciónRESUMEN
Foot-and-mouth disease (FMD) is an acute epidemic that spreads rapidly among cattle and pigs. In 2014, in Korea, despite enforced vaccination, the type O Southeast Asia (SEA) topotype viruses (Mya-98 lineage) infected mainly cattle and pigs simultaneously, thereby causing enormous damage. If a vaccine that is completely protective against this FMD virus is developed and used, it can become a very important preventive measure in Asia, which is where this type of virus mainly circulates. The SEA topotype has been steadily evolving and transforming into new variations since it became epidemic in Asia. Therefore, it became necessary to develop a new vaccine that could provide protection against the FMD virus strain that was responsible for the 2014-2015 outbreak in Korea. This study aimed to develop a vaccine that would provide complete protection against the SEA topotype FMD virus to control sporadic FMD outbreaks, which occur despite the enforcement of vaccination, and to completely prevent virus shedding, thereby preventing the virus from spreading. The vaccine candidate virus developed in this study showed low pathogenicity and can be distinguished from the wild-type FMD virus strain. The developed vaccine was able to protect mice from SEA and Middle East-South Asia topotype virus strains and induced high titers of antibodies against both virus strains in pigs, thereby confirming the sufficiency of its protective function. In particular, the results of the SEA topotype virus challenge test in pigs revealed that perfect immunity was created in the vaccinated pigs, without virus shedding and viremia.
Asunto(s)
Virus de la Fiebre Aftosa/inmunología , Fiebre Aftosa/prevención & control , Enfermedades de los Porcinos/prevención & control , Vacunas Virales/farmacología , Animales , Fiebre Aftosa/inmunología , Fiebre Aftosa/virología , República de Corea , Porcinos , Enfermedades de los Porcinos/inmunología , Enfermedades de los Porcinos/virologíaRESUMEN
Foot-and-mouth disease (FMD) is a highly contagious disease and causes economic damage at a national level. In particular, the type O FMD virus (FMDV) is a serotype that causes FMD outbreaks most frequently in the world. In recent years, Southeast Asia (SEA), Middle East-South Asia (ME-SA), and Cathay topotype-mediated FMD are prevalent in Asia, among which the SEA and ME-SA topotypes cause a majority of the outbreaks. The SEA topotype virus is more likely to infect both cattle and pigs simultaneously, thereby resulting in more severe damages; thus, it is necessary to study the protection ability of the candidate vaccines of this topotype after immunization. In this study, an experimental vaccine for pigs was produced using a vaccine strain that contains the structural protein of the O Taiwan97 strain, which was derived from the Cathay topotype, and its effect was evaluated. In the immunization test in pigs and cattle, the antibody titers were found to be elevated two weeks after immunization and very high titers of neutralizing antibodies were formed after four weeks. After the second inoculation, very high titers of neutralizing antibodies were produced in both species in the fourth week after immunization, and the antibodies maintained for up to six months and three months in cattle and pigs, respectively. No significant immunological difference in antibody production was observed in cattle and pigs. This study confirmed that complete protection from the challenge of the SEA topotype virus (O/Jincheon/SKR/2014), although the antibody titers against O/Jincheon/SKR/2014 strain were not that high, was achieved through immunization with the newly developed Cathay topotype vaccine in pigs.
Asunto(s)
Virus de la Fiebre Aftosa/clasificación , Fiebre Aftosa/prevención & control , Enfermedades de los Porcinos/prevención & control , Vacunas Virales/inmunología , Animales , Anticuerpos Antivirales/sangre , Fiebre Aftosa/epidemiología , Fiebre Aftosa/virología , Ratones , Ratones Endogámicos ICR , República de Corea/epidemiología , Porcinos , Enfermedades de los Porcinos/virología , Esparcimiento de VirusRESUMEN
Foot-and-mouth disease (FMD) is an acute infectious disease occurring in cloven-hoofed animals. There are many variations of the virus, making it difficult to protect against the various strains with one virus vaccine. The immunogenicity has generally been evaluated in pigs using neutralizing antibodies to determine the protection level against foot-and-mouth disease virus type O. Therefore, the vaccine from the chimeric vaccine strain of ME-SA (VP4, VP2, and VP3) and SEA (VP1) topotypes developed in this study is expected to be able to protect with high neutralizing antibody titers against most of the eight FMD viruses of the four different topotypes (ME-SA, SEA, Cathay, and EURO-SA) of type O in pigs. This is a new technique for powerful vaccine development, with multiple preventive roles against various epidemic FMD strains.
Asunto(s)
Virus de la Fiebre Aftosa/clasificación , Fiebre Aftosa/prevención & control , Vacunas Virales/inmunología , Animales , Proteínas Recombinantes/inmunología , Porcinos , Enfermedades de los Porcinos/prevención & control , Enfermedades de los Porcinos/virologíaRESUMEN
Foot-and-mouth disease virus (FMDV) is the cause of an economically devastating disease in major cloven-hoofed livestock. Although type C foot-and-mouth disease (FMD) has not occurred anywhere worldwide since 2004, the antigen bank should be preserved in preparation for an unexpected outbreak. We therefore conducted experiments to develop inactivated vaccines that are safer and exhibit improved characteristics over existing vaccines. Our previous study showed that the replacement of the capsid-encoding gene (P1) from the vaccine strain O1 Manisa could be rescued successfully from the vaccine strains. In addition, novel point mutation in the 3C region in the virus genome, for induction of properties with low pathogenesis to create a safe vaccine, and 3B1B2 replacement, for differential diagnosis with the wild type virus, were performed. The modified FMD vaccine strain, C3 Resende-R, was shown to provide lower pathogenesis in young mice than the wild-type virus. To identify the immune responses after vaccination with 146S antigen (15⯵g/mL/dose), we conducted a virus neutralization test using serum from pigs and cattle vaccinated with the inactivated vaccine. The neutralizing titers in the cattle were higher than those in the pigs and maintained mean antibody titers of around 1:100 until the end of the experiment. The vaccine showed protection capability of 16 PD50 against C3 Resende virus in the pigs. The replacement of the structural protein-coding gene for the new FMDV was a useful tool in the development of an effective vaccine candidate strain. This inactivated vaccine will be used for the establishment of a safe vaccine strain for the antigen bank.
Asunto(s)
Anticuerpos Antivirales/sangre , Fiebre Aftosa/prevención & control , Vacunas Virales/inmunología , Animales , Animales Lactantes , Bovinos , Femenino , Virus de la Fiebre Aftosa , Ratones , Ratones Endogámicos C57BL , Ratones Endogámicos ICR , Pruebas de Neutralización , Porcinos , Vacunas de Productos Inactivados/inmunologíaRESUMEN
In many countries, vaccines are used for the prevention of foot-and-mouth disease (FMD). However, because there is no protection against FMD immediately after vaccination, research and development on antiviral agents is being conducted to induce protection until immunological competence is produced. This study tested whether well-known chemicals used as RNA virus treatment agents had inhibitory effects on FMD viruses (FMDVs) and demonstrated that ribavirin showed antiviral effects against FMDV in vitro/in vivo. In addition, it was observed that combining the administration of the antiviral agents orally and complementary therapy with vaccines synergistically enhanced antiviral activity and preserved the survival rate and body weight in the experimental animals. Antiviral agents mixed with an adjuvant were inoculated intramuscularly along with the vaccines, thereby inhibiting virus replication after injection and verifying that it was possible to induce early protection against viral infection prior to immunity being achieved through the vaccine. Finally, pigs treated with antiviral agents and vaccines showed no clinical signs and had low virus excretion. Based on these results, it is expected that this combined approach could be a therapeutic and preventive treatment for early protection against FMD.
Asunto(s)
Antivirales/uso terapéutico , Virus de la Fiebre Aftosa , Fiebre Aftosa/prevención & control , Ribavirina/uso terapéutico , Vacunas Virales/uso terapéutico , Animales , Antivirales/administración & dosificación , Línea Celular , Sinergismo Farmacológico , Fiebre Aftosa/tratamiento farmacológico , Inyecciones Intramusculares , Inyecciones Intraperitoneales , Ratones , Ratones Endogámicos C57BL , Ribavirina/administración & dosificación , Porcinos , Porcinos Enanos , Vacunas Virales/administración & dosificaciónRESUMEN
On December 3, 2014, a type O foot-and-mouth disease (FMD) outbreak began in Korea. Although vaccinations were administered, FMD cases increased steadily for five months, and reached 185 cases by April 2015. Most of the affected animals were pigs, which are vulnerable to vaccination. The FMD virus belonged to the South-East Asia (SEA) topotype that had been observed three times in Korea between April 2010 and July 2014. However, the FMD virus isolated in December 2014 had a unique feature; that is, partial deletion of the 5´ non-coding region, a deletion not seen in previous SEA topotype isolates identified in Korea. We conclude that this outbreak included the introduction of a new FMD strain to Korea, and that Korea was now affected by genetically similar FMD virus strains that are related to those from neighboring countries.
Asunto(s)
Virus de la Fiebre Aftosa , Fiebre Aftosa/prevención & control , Vacunas Virales/uso terapéutico , Animales , Anticuerpos Antivirales/inmunología , Bovinos , Enfermedades de los Bovinos/epidemiología , Enfermedades de los Bovinos/prevención & control , Enfermedades de los Bovinos/virología , Brotes de Enfermedades/veterinaria , Ensayo de Inmunoadsorción Enzimática/veterinaria , Fiebre Aftosa/epidemiología , Virus de la Fiebre Aftosa/genética , Virus de la Fiebre Aftosa/inmunología , República de Corea/epidemiología , Porcinos , Enfermedades de los Porcinos/epidemiología , Enfermedades de los Porcinos/prevención & control , Enfermedades de los Porcinos/virologíaRESUMEN
Foot-and-mouth disease (FMD) is the cause of an economically devastating animal disease. With commercial inactivated FMD vaccines, the protection against FMD virus (FMDV) begins a minimum of 4 days post vaccination (dpv). Therefore, antiviral agents could be proposed for rapid protection and to reduce the spread of FMDV during outbreaks until vaccine-induced protective immunity occurs. In previous studies, we have developed two recombinant adenoviruses that simultaneously express porcine interferon-α and interferon-γ (Ad-porcine IFN-αγ) and multiple siRNAs that target the non-structural protein-regions of FMDV (Ad-3siRNA), and we have shown that the combination of the two antiviral agents (referred to here as Ad combination) induced robust protection against FMDV in pigs. In an attempt to provide complete protection against FMDV, we co-administered Ad combination and the FMD vaccine to mice and pigs. In the C57BL/6 mice model, we observed rapid and continuous protection against homologous FMDV challenge from 1 to 3 dpv-the period in which vaccine-mediated immunity is absent. In the pig experiments, we found that most of the pigs (five out of six) that received vaccine + Ad combination and were challenged with FMDV at 1 or 2 dpv were clinically protected from FMDV. In addition, most of the pigs that received vaccine + Ad combination and all pigs inoculated with the vaccine only were clinically protected from an FMDV challenge at 7 dpv. We believe that the antiviral agent ensures early protection from FMDV, and the vaccine participates in protection after 7 dpv. Therefore, we can say that the combination of the FMD vaccine and effective antiviral agents may offer both fast-acting and continuous protection against FMDV. In further studies, we plan to design coadministration of Ad combination and novel vaccines.
Asunto(s)
Antivirales/farmacología , Virus de la Fiebre Aftosa/efectos de los fármacos , Fiebre Aftosa/prevención & control , Vacunación , Vacunas Virales/farmacología , Adenoviridae/genética , Animales , Anticuerpos Neutralizantes , Anticuerpos Antivirales/inmunología , Antivirales/administración & dosificación , Citocinas/sangre , Combinación de Medicamentos , Virus de la Fiebre Aftosa/patogenicidad , Células HEK293 , Humanos , Inyecciones Intramusculares , Interferón-alfa/farmacología , Interferón gamma/farmacología , Ratones , Ratones Endogámicos C57BL , ARN Interferente Pequeño/farmacología , Recombinación Genética , Tasa de Supervivencia , Porcinos , Vacunas de Productos Inactivados/farmacología , Proteínas no Estructurales Virales/inmunología , Vacunas Virales/administración & dosificación , Vacunas Virales/inmunologíaRESUMEN
With the current commercial foot-and-mouth disease vaccine, inoculating twice increases the formation of denatured meat due to granuloma or residual adjuvant at the injection site in pigs, resulting in economic loss. Therefore, we investigated protective antibody levels after reducing the amount of adjuvant in the vaccine. Field applicability of the experimental vaccine, made with a new adjuvant ISA 201, was tested by vaccinating farm animals with half-volume doses (1 mL/animal) of commercial vaccine and monitoring their immunogenicity. Among pigs, the group that received a half-volume dose showed similar or higher titers of structural protein antibody and neutralizing antibody than those receiving the standard dose (2 mL). In pigs, the durable effects of antibody titer of the reduced vaccine volume did not diminish up to the time of slaughter. Among cattle, boosting with a second 1 mL vaccine increased virus neutralizing antibody for the protective effects. The boosting effects were more marked in cattle than in pigs. The immune responses differed between species with the effect of the half-volume vaccination being lower in cattle than in pigs. In conclusion, the immune response to the half-volume vaccine was similar to that from the standard volume vaccine in pigs, but not in cattle.
Asunto(s)
Enfermedades de los Bovinos/prevención & control , Virus de la Fiebre Aftosa/inmunología , Fiebre Aftosa/prevención & control , Enfermedades de los Porcinos/prevención & control , Vacunas Virales/uso terapéutico , Animales , Formación de Anticuerpos/inmunología , Bovinos , Enfermedades de los Bovinos/inmunología , Enfermedades de los Bovinos/virología , Relación Dosis-Respuesta Inmunológica , Fiebre Aftosa/inmunología , Porcinos , Enfermedades de los Porcinos/inmunología , Enfermedades de los Porcinos/virología , Vacunas Virales/administración & dosificación , Vacunas Virales/inmunologíaRESUMEN
The complete genome sequence of a foot-and-mouth disease (FMD) serotype SAT3 virus ZIM/4/81, which belongs to a topotype 1 (SEZ), is reported here.
RESUMEN
Efficacy evaluation of foot-and-mouth disease (FMD) vaccines has been conducted in target animals such as cows and pigs. In particular, handling FMD virus requires a high level of biosafety management and facilities to contain the virulent viruses. The lack of a laboratory animal model has resulted in inconvenience when it comes to using target animals for vaccine evaluation, bringing about increased cost, time and labor for the experiments. The FMD mouse model has been studied, but most FMD virus (FMDV) strains are not known to cause disease in adult mice. In the present study, we created a series of challenge viruses that are lethal to adult C57BL/6 mice. FMDV types O, A, and Asia1, which are related to frequent FMD outbreaks, were adapted for mice and the pathogenesis of each virus was evaluated in the mouse model. Challenge experiments after vaccination using in-house and commercial vaccines demonstrated vaccine-mediated protection in a dose-dependent manner. In conclusion, we propose that FMD vaccine evaluation should be carried out using mouse-adapted challenge viruses as a swift, effective efficacy test of experimental or commercial vaccines.
Asunto(s)
Modelos Animales de Enfermedad , Virus de la Fiebre Aftosa/clasificación , Fiebre Aftosa/prevención & control , Vacunas Virales/inmunología , Animales , Ratones Endogámicos C57BL , Serogrupo , Vacunas de Productos Inactivados/inmunologíaRESUMEN
Foot-and-mouth disease (FMD) is a highly contagious and economically devastating disease that affects cloven-hoofed animals worldwide. Construction and purification of stable antigen for vaccine are necessary but technically difficult and laborious. Here, we have tried to investigate an alternative method by inserting a hexa-histidine tag (6xHIS) in the VP1 C-terminal for easy purification and replacing two amino acids of VP1/VP2 to enhance the stability of the capsid of the FMD virus (FMDV) Asia1/MOG/05. In addition, infectious 6xHIS-tagged stable (S/T) FMDVs were maintained under acidic conditions (pH 6.0) and were readily purified from small-scale cultures using a commercial metal-affinity column. The groups vaccinated with the S/T FMDV antigen showed complete protection comparing to low survival rate in the group vaccinated with non-S/T FMDV against lethal challenge with Asia1 Shamir in mice. Therefore, the present findings indicate that the stabilized and tagged antigen offers an alternative to using the current methods for antigen purification and enhancement of stability and has potential for the development of a new FMD vaccine.
Asunto(s)
Antígenos Virales/inmunología , Virus de la Fiebre Aftosa/genética , Virus de la Fiebre Aftosa/inmunología , Histidina/química , Potencia de la Vacuna , Vacunas Virales/inmunología , Animales , Anticuerpos Antivirales/sangre , Antígenos Virales/aislamiento & purificación , Proteínas de la Cápside/genética , Fiebre Aftosa/prevención & control , Fiebre Aftosa/virología , Concentración de Iones de Hidrógeno , Ratones , Estabilidad Proteica , Vacunas Sintéticas , Vacunas Virales/administración & dosificación , Vacunas Virales/químicaRESUMEN
Foot-and-mouth disease (FMD) is a highly contagious vesicular disease of livestock caused by a highly variable RNA virus, foot-and-mouth disease virus (FMDV). One of the targets to suppress expansion of and to control FMD is 3D polymerase (FMDV 3Dpol). In this study, 2-amino-4-arylthiazole derivatives were synthesized and evaluated for their inhibitory activity against FMDV 3Dpol. Among them, compound 20i exhibited the most potent functional inhibition (IC50 = 0.39 µM) of FMDV 3D polymerase and compound 24a (EC50 = 13.09 µM) showed more potent antiviral activity than ribavirin (EC50 = 1367 µM) and T1105 (EC50 = 347 µM) with IBRS-2 cells infected by the FMDV O/SKR/2010 strain.